Douglas Johnson Archives

Several from VUMC among most highly cited researchers

Nov. 17, 2022—Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis

Nov. 16, 2022—Researchers from from Vanderbilt-Ingram Cancer Center have identified the mechanism for the deadly heart inflammation myocarditis.

Among those honored at last week’s event were (front row, from left) Pratik Pandharipande, MD, MSCI, Seth Smith, PhD, Kimberly Vinson, MD, Jessica Ancker, PhD, MPH, Nancy Davis, MD, Uyen Tran, MD, Tonia Rex, PhD, Adam Yock, PhD, DABR, Christopher Williams, MD, PhD, David Raiford, MD, (back row, from left) Adam Wright, PhD, Paul Moore, MD, Daniel Fabbri, PhD, John Penn, PhD, Rebecca Swan, MD, Alexander Gelbard, MD, Jennifer Lindsey, MD, Michael Savona, MD, Kathryn Lindley, MD, Sarah Jaser, PhD, and Douglas Johnson, MD, MSCI.

Directorships honor VUMC leaders and philanthropic partners

Sep. 8, 2022—by Doug Campbell Last week, Vanderbilt University Medical Center held a Directorship Celebration to honor 21 leaders from across the enterprise in clinical care, research, education and administration. “Endowed directorships support the excellence of our leading physicians and scientists,” said Jeff Balser, MD, PhD, CEO of VUMC and Dean of Vanderbilt University School of Medicine....

Abramson, Eng, Johnson named to new VICC roles

Aug. 18, 2022—Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles.

Directorships honor VUMC leaders and philanthropic partners

Dec. 2, 2021—Ten Vanderbilt University Medical Center leaders from across the enterprise in clinical care, research, education and administration have been named as holders of endowed directorships.

Seven from VUMC among most highly cited researchers

Nov. 18, 2021—Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Mar. 25, 2021—Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

The study team included, from left, Douglas Johnson, MD, Dan Roden, MD, Javid Moslehi, MD, Joe-Elie Salem, MD, PhD, and Ali Manouchehri, MD.

Study identifies targeted therapy’s cardiac risks

Sep. 25, 2019—After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

Encephalitis identified as rare toxicity of immunotherapy treatment

Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

Medical Societies honor multiple Vanderbilt faculty

Apr. 18, 2019—Several Vanderbilt faculty members were recently honored during the joint annual meeting of the Association of American Physicians (AAP) and American Society for Clinical Investigation (ASCI).

Immunotherapies linked to specific heart complications

Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.

Study tracks incidence, timing of immunotherapy-related deaths

Sep. 13, 2018—Vanderbilt-Ingram Cancer Center researchers have answered questions about the incidence and timing of rare but sometimes fatal reactions to the most widely prescribed class of immunotherapies.